ABIVAX press release
Publication of an expert opinion in the journal JCC on obefazimod as a therapeutic option for the treatment of patients with UC.
The authors of the expert article published in the Journal of Crohn’s and Colitis include European and North American thought leaders in the field of inflammatory bowel disease.
Experts claim that obefazimod is the first drug in its therapeutic class with an innovative and very promising mechanism of action for the treatment of patients with ulcerative colitis.
Experts expect results from the ongoing Phase 3 program with obefazimod in UC to confirm its potential to relieve patients of their symptoms quickly and sustainably.